Daxx Antibody

Daxx (death-domain-associated protein) was originally identified as a cytoplasmic protein that binds to the death domain of the transmembrane death receptor Fas. It is now that known that the a large porportion of Daxx molecules are nuclear and associate with the promyelocytic leukaemia nuclear body (PML-NB) and other subnuclear domains (reviewed in Salomoni and Khelifi). The promyelocytic leukemia protein Pml is an essential component of the PML-NB. Data suggests that certain stimuli including Fas stimulation, causes Daxx to be translocated from the nucleus to the cytoplasm. Daxx is ubiquitously expressed, and particularly high levels of Daxx have been reported in the thymus and testes. At the cellular level Daxx may be found in cytoplasm and within heterochromatic regions of the nucleus. Daxx has been reported to interact and co-localize with Pml in the nucleus of tumor cell lines and primary cells. Pml is necessary for Fas-induced cell death and Daxx pro-apoptotic functions. Daxx is thought to have both pro- and anti-apoptotic functions depending on the stimulus and the cell type. Daxx pro-apoptotic functions appear to occur in both the cytoplasm and nucleus. Although the mechanisms remain to be fully elucidated, research indicates that Daxx plays a role in the pathology of human diseases including cancer and neurodegerative disorders. Human Daxx is a 740 amino acid protein (GenBank no. gi/62898369).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: IF/IHC, WB.

Showing Publications 1 - 9 of 9.

Publications using NBP1-85309	Applications	Species
Robert Siddaway, Scott Milos, Étienne Coyaud, Hwa Young Yun, Shahir M. Morcos, Sanja Pajovic, Eric I. Campos, Brian Raught, Cynthia Hawkins The in v ivo Interaction Landscape of Histones H3.1 and H3.3 Molecular & Cellular Proteomics : MCP 2022-09-09 [PMID: 36089195]
Masayuki Yoshida, Reiko Ogawa, Hiroshi Yoshida et al. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast. British Journal of Cancer 2015-09-10 [PMID: 26355235] (IF/IHC, Human)	IF/IHC	Human
Napier CE, Huschtscha LI, Harvey A et al. ATRX represses alternative lengthening of telomeres. Oncotarget 2015-06-30 [PMID: 26001292] (WB, Human)	WB	Human
Pipinikas CP, Dibra H, Karpathakis A et al. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocr Relat Cancer 2015-06-01 [PMID: 25900181] (IF/IHC, Human)	IF/IHC	Human
Fishbein L, Khare S, Wubbenhorst B et al. Whole exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun 2015-01-21 [PMID: 25608029] (IF/IHC, Human)	IF/IHC	Human
Stepp WH, Meyers JM, McBride AA. Sp100 Provides Intrinsic Immunity against Human Papillomavirus Infection. mBio 2013-11-05 [PMID: 24194542]
de Wilde RF, Heaphy CM, Maitra A et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol 2012-07-01 [PMID: 22575867]
Schwartzentruber J, Korshunov A, Liu XY et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012-01-29 [PMID: 22286061]
Heaphy CM, de Wilde RF, Jiao Y et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011-07-22 [PMID: 21719641]

Array NBP1-85309

• Daxx Antibodies
• Daxx Lysates
• Daxx Proteins